The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
950
June 9, 1995
View Complete Issue         Table of Contents 2019 
Abciximab to Prevent Vessel Closure After Angioplasty
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Abciximab to Prevent Vessel Closure After Angioplasty
June 9, 1995 (Issue: 950)
Abciximab (ab sik si mab; ReoPro - Centocor), the Fab (fragment antigen binding) fragment of the chimeric human-murine monoclonal antibody 7E3 (c7E3 Fab), has been approved by the US Food and Drug Administration as an adjunct to percutaneous ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Abciximab to Prevent Vessel Closure After Angioplasty
Article code: 950b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.